Latest news and press releases about BioCardia, Inc. (BCDA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions.
Price
| Price | $1.25 |
| Market Cap | $19M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 10.78 |
| EV / EBITDA | -0.82 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -919.33% |
| Return on Invested Capital | -581.73% |
| Return on Assets | -241.08% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACXP · ADIL · ALZN · APRE · APVO · CELZ · HCWB
Explore sector: Healthcare · Biotechnology
More sections of BCDA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks